Japan Influenza Vaccine Market Size & Outlook, 2023-2030
Japan influenza vaccine market, 2018-2030 (US$M)
Related Markets
Japan influenza vaccine market highlights
- The Japan influenza vaccine market generated a revenue of USD 249.7 million in 2023 and is expected to reach USD 397.2 million by 2030.
- The Japan market is expected to grow at a CAGR of 6.9% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Influenza vaccine market data book summary
| Market revenue in 2023 | USD 249.7 million |
| Market revenue in 2030 | USD 397.2 million |
| Growth rate | 6.9% (CAGR from 2023 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, Japan accounted for 3.2% of the global influenza vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 477.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan influenza vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza vaccine market will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 91.67% in 2023. Horizon Databook has segmented the Japan influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the most technologically advanced countries in Asia Pacific. Its influenza vaccine market is expected to grow rapidly over the forecast period owing to high government spending to reduce the flu burden. Multiple initiatives, such as government grants to various research institutes and companies, can help develop practical solutions for the influenza burden in the country.
Similarly, in October 2022, the Government of Japan started preparations against the flu and COVID-19. Under these preparations, the government recommended people get vaccinated against the flu if they notice any symptoms.
Furthermore, several organic and inorganic initiatives undertaken by leading participants to strengthen their presence are driving the country’s market. For instance, in November 2022, Shionogi & Co., Ltd. announced that it applied for the approval of S-268019, a protein-based vaccine for use as a booster dose against COVID-19.
Reasons to subscribe to Japan influenza vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan influenza vaccine market databook
-
Our clientele includes a mix of influenza vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan influenza vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Japan influenza vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan influenza vaccine market size, by vaccine type, 2018-2030 (US$M)
Japan Influenza Vaccine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
